Immupharma Regulatory News (IMM)

ImmuPharma plc

Cancer Compound IPP-204106 paper published in prestigious medical journal

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company" or the "Group"), the specialist discovery and development pharmaceutical company is pleased to announce the publication of a scientific paper on its cancer compound IPP-204106 in Cancer Research, a prestigious medical journal of the American Association for Cancer Research.

The publication was entitled "A Simple Approach to Cancer Therapy Afforded by Multivalent Pseudopeptides That Target Cell-Surface Nucleoproteins" and was authored by a number of researchers working at or with the CNRS, the research institution with which ImmuPharma is collaborating.

The key findings of this study are that the compound (referred to in the paper as "N6L"):

·; inhibits growth of several tumour cell lines, xenograft models and blocks angiogenesis;

·; rapidly localizes selectively in tumour tissue;

·; promotes apoptosis (the death of cells, a key approach in the treatment of cancer);

·; has a novel mechanism of action, acting on nucleophosmin and nucleolin;

The drug candidate is currently in a phase I/II clinical trial in cancer patients in France. Details of the current study and interim results were announced by ImmuPharma in the past months.

Dr. Robert Zimmer, MD, PhD, ImmuPharma's President and head of R&D said: "We are honoured to see the publication of our promising potential cancer treatment results and mechanism in an important medical journal respected by the international medical community. We are even more pleased to see that our compound was chosen to be on the cover of the journal. It is a pleasing validation of years of research by our scientific collaborators and gives us further confidence in developing the compound".

The publication can be seen at http://cancerres.aacrjournals.org/content/71/9/3296 and the website of Cancer Research is http://cancerres.aacrjournals.org/

Key facts for the CNRS appear at http://www.cnrs.fr/en/aboutCNRS/key-figures.htm

For further information, please contact:

ImmuPharma PLC:

Dr Robert Zimmer, President & Chief Scientific Officer + 33 389 32 76 50

Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080

Richard Warr, Chairman +44 20 7152 4080

Buchanan Communications

Lisa Baderoon, Mark Court, Jessica Fontaine +44 20 7466 5000

Panmure, Gordon & Co., NOMAD & Broker

Andrew Burnett, Rakesh Sharma +44 20 7459 3600

Bank Espirito Santo (Execution Noble)

James Bromhead, Richard Crawley +44 20 7456 9191